Solid Biosciences Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Solid Biosciences Inc. (SLDB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-19
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $407.00K, a 236.36% increase from fiscal 2023.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $121.00K, a 99.58% decline from fiscal 2022.
- Solid Biosciences Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $29.13M, a 9295.48% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $0.00 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $0.00 derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | -$10.00K derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | -$10.00K derived: sum of 3 quarters · filed 2026-03-19 | $407.00K 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$10.00K derived: sum of 2 quarters · filed 2025-11-03 | $407.00K 10-Q · filed 2025-11-03 | $407.00K derived: sum of 4 quarters · filed 2025-11-03 | |||
| 2024-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $407.00K 10-Q · filed 2025-08-12 | $407.00K derived: sum of 3 quarters · filed 2025-08-12 | $389.00K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $417.00K 10-Q · filed 2025-05-15 | $417.00K derived: sum of 2 quarters · filed 2025-05-15 | $399.00K derived: sum of 3 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$18.00K derived: sum of 2 quarters · filed 2025-03-06 | $121.00K 10-K · filed 2025-03-06 | $410.00K 10-K · filed 2024-03-13 | |||
| 2023-09-30 | -$18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $121.00K 10-Q · filed 2024-11-06 | $428.00K 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $139.00K 10-Q · filed 2024-08-13 | $417.00K 10-Q · filed 2023-08-14 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $29.13M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $29.13M 10-Q · filed 2023-11-08 | |||||
| 2022-06-30 | $29.13M 10-Q · filed 2023-08-14 | ||||||
| 2021-12-31 | $310.00K 10-K · filed 2024-03-13 | ||||||
| 2020-12-31 | $1.63M 10-K · filed 2023-03-23 | ||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-14 | $0.00 derived: sum of 3 quarters · filed 2022-03-14 | $1.63M 10-K · filed 2022-03-14 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $1.63M 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.63M 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | $1.63M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |